智通财经APP讯，康宁杰瑞制药-B(09966)发布公告，公司自主研发的程序性死亡配体1(PD-L1)╱ 血管内皮生长因子受体2(VEGFR2)双特异性抗体偶联药物(ADC(s))JSKN027治疗晚期恶性实体瘤的I期临床研究(研究编号：JSKN027-101)已成功完成首例患者给药。JSKN027是公司第五款进入临床研究阶段的ADC，也是全球首款进入临床研究阶段的PD-L1/VEGFR2双抗ADC。基于其细胞毒杀伤、抗血管生成及免疫调节等多重作用机制，JSKN027有望为多种实体瘤治疗提供新的治疗选择。
JSKN027-101是一项在晚期恶性实体瘤受试者中开展的开放、多中心、I期临床研究，分为剂量递增和剂量扩展两个阶段，旨在评估JSKN027在晚期恶性实体瘤患者中的安全性、耐受性、药代动力学(PK)╱药效学(PD)及初步抗肿瘤活性，并确定最大耐受剂量(MTD)及╱或推荐II期剂量(RP2D)。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.